XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies - Summary of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues:        
Total revenues, net $ 110,565,000 $ 2,168,000 $ 227,198,000 $ 213,288,000
Cost of revenues        
Total cost of revenues 3,653,000 598,000 6,292,000 1,196,000
Total segment research and development 111,231,000 114,695,000 222,662,000 255,667,000
Selling, general and administrative 129,154,000 59,523,000 235,519,000 125,330,000
Restructuring, impairment and related charges 805,000 2,891,000 1,375,000 6,291,000
Total operating costs and expenses 244,843,000 177,707,000 465,848,000 388,484,000
Loss from operations (134,278,000) (175,539,000) (238,650,000) (175,196,000)
Other income (expense), net:        
Interest income 3,898,000 5,195,000 9,283,000 9,270,000
Interest expense (37,637,000) (22,937,000) (79,778,000) (46,408,000)
Gain on deconsolidation of a subsidiary 0 126,294,000 0 126,294,000
Losses on extinguishments of debt 0 0 (21,155,000) (26,590,000)
Net loss from equity method investments (20,189,000) (7,925,000) (35,745,000) (7,925,000)
Other income (expense), net 6,548,000 (632,000) 14,779,000 8,851,000
Total other income (expense), net (47,380,000) 99,995,000 (112,616,000) 63,492,000
Loss before income taxes (181,658,000) (75,544,000) (351,266,000) (111,704,000)
Income tax expense 2,100,000 0 2,100,000 0
Net loss (183,758,000) (75,544,000) (353,366,000) (111,704,000)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 1,855,000 2,088,000 4,041,000 3,032,000
Net loss attributable to common stockholders of BridgeBio (181,903,000) (73,456,000) (349,325,000) (108,672,000)
Net Product Revenue        
Revenues:        
Total revenues, net 71,501,000 0 108,240,000 0
Royalty Revenue        
Revenues:        
Total revenues, net 1,624,000 0 1,828,000 0
Cost of License, Services and Royalty Revenue        
Cost of revenues        
Total cost of revenues 805,000 598,000 1,410,000 1,196,000
Cost of Goods Sold        
Cost of revenues        
Total cost of revenues 2,848,000 0 4,882,000 0
Reportable Segment        
Revenues:        
Total revenues, net 110,565,000 2,168,000 227,198,000 213,288,000
Cost of revenues        
Total cost of revenues 3,653,000 598,000 6,292,000 1,196,000
Total segment research and development 111,231,000 114,695,000 222,662,000 255,667,000
Selling, general and administrative 129,154,000 59,523,000 235,519,000 125,330,000
Restructuring, impairment and related charges 805,000 2,891,000 1,375,000 6,291,000
Total operating costs and expenses 244,843,000 177,707,000 465,848,000 388,484,000
Loss from operations (134,278,000) (175,539,000) (238,650,000) (175,196,000)
Other income (expense), net:        
Interest income 3,898,000 5,195,000 9,283,000 9,270,000
Interest expense (37,637,000) (22,937,000) (79,778,000) (46,408,000)
Gain on deconsolidation of a subsidiary 0 126,294,000 0 126,294,000
Losses on extinguishments of debt 0 0 (21,155,000) (26,590,000)
Net loss from equity method investments (20,189,000) (7,925,000) (35,745,000) (7,925,000)
Other income (expense), net 6,548,000 (632,000) 14,779,000 8,851,000
Total other income (expense), net (47,380,000) 99,995,000 (112,616,000) 63,492,000
Loss before income taxes (181,658,000) (75,544,000) (351,266,000) (111,704,000)
Income tax expense 2,100,000 0 2,100,000 0
Net loss (183,758,000) (75,544,000) (353,366,000) (111,704,000)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 1,855,000 2,088,000 4,041,000 3,032,000
Net loss attributable to common stockholders of BridgeBio (181,903,000) (73,456,000) (349,325,000) (108,672,000)
Reportable Segment | Acoramidis For Attr Cm        
Cost of revenues        
Total segment research and development 28,269,000 36,798,000 52,661,000 76,540,000
Reportable Segment | Infigratinib for Achondroplasia and Hypochondroplasia        
Cost of revenues        
Total segment research and development 30,191,000 22,098,000 58,125,000 43,283,000
Reportable Segment | BBP-418 for LGMD2I/R9        
Cost of revenues        
Total segment research and development 11,243,000 10,773,000 25,452,000 20,791,000
Reportable Segment | Encaleret for ADH1        
Cost of revenues        
Total segment research and development 13,128,000 10,608,000 28,587,000 23,152,000
Reportable Segment | Other Development Programs        
Cost of revenues        
Total segment research and development 10,536,000 9,693,000 21,966,000 41,977,000
Reportable Segment | Other Research Programs        
Cost of revenues        
Total segment research and development 17,864,000 24,725,000 35,871,000 49,924,000
Reportable Segment | License and Services Revenue        
Revenues:        
Total revenues, net 37,440,000 2,168,000 117,130,000 213,288,000
Reportable Segment | Net Product Revenue        
Revenues:        
Total revenues, net 71,501,000 0 108,240,000 0
Reportable Segment | Royalty Revenue        
Revenues:        
Total revenues, net 1,624,000 0 1,828,000 0
Reportable Segment | Cost of License, Services and Royalty Revenue        
Cost of revenues        
Total cost of revenues 805,000 598,000 1,410,000 1,196,000
Reportable Segment | Cost of Goods Sold        
Cost of revenues        
Total cost of revenues $ 2,848,000 $ 0 $ 4,882,000 $ 0